CY1119051T1 - Αντισωματα anti-c4.4a και χρησεις αυτων - Google Patents

Αντισωματα anti-c4.4a και χρησεις αυτων

Info

Publication number
CY1119051T1
CY1119051T1 CY20171100712T CY171100712T CY1119051T1 CY 1119051 T1 CY1119051 T1 CY 1119051T1 CY 20171100712 T CY20171100712 T CY 20171100712T CY 171100712 T CY171100712 T CY 171100712T CY 1119051 T1 CY1119051 T1 CY 1119051T1
Authority
CY
Cyprus
Prior art keywords
antibodies
binding domains
antigen
disorders
cancer
Prior art date
Application number
CY20171100712T
Other languages
Greek (el)
English (en)
Inventor
Lars Linden
Yong-Jiang Cao
Gabriele Leder
Beatrix Stelte-Ludwig
Axel Harrenga
Ricarda Finnern
Frank Dittmer
Anke Mayer-Bartschmid
Juergen Franz
Simone Greven
Jörg Willuda
Jan Tebbe
Original Assignee
Bayer Pharma Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma Aktiengesellschaft filed Critical Bayer Pharma Aktiengesellschaft
Publication of CY1119051T1 publication Critical patent/CY1119051T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CY20171100712T 2009-12-09 2017-07-04 Αντισωματα anti-c4.4a και χρησεις αυτων CY1119051T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP09178474 2009-12-09
EP10170797 2010-07-26
PCT/EP2010/069216 WO2011070088A1 (en) 2009-12-09 2010-12-08 Anti-c4.4a antibodies and uses thereof
EP10798996.4A EP2510012B1 (en) 2009-12-09 2010-12-08 Anti-c4.4a antibodies and uses thereof

Publications (1)

Publication Number Publication Date
CY1119051T1 true CY1119051T1 (el) 2018-01-10

Family

ID=43629588

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20171100712T CY1119051T1 (el) 2009-12-09 2017-07-04 Αντισωματα anti-c4.4a και χρησεις αυτων

Country Status (27)

Country Link
US (2) US20120321619A1 (enExample)
EP (2) EP2510012B1 (enExample)
JP (3) JP5989544B2 (enExample)
KR (1) KR101931820B1 (enExample)
CN (1) CN102812047B (enExample)
AR (1) AR079340A1 (enExample)
AU (1) AU2010329904B2 (enExample)
BR (1) BR112012013915A8 (enExample)
CA (1) CA2783338A1 (enExample)
CY (1) CY1119051T1 (enExample)
DK (1) DK2510012T3 (enExample)
ES (1) ES2632748T3 (enExample)
HR (1) HRP20170973T1 (enExample)
HU (1) HUE034847T2 (enExample)
IL (1) IL219801A (enExample)
IN (1) IN2012DN05175A (enExample)
LT (1) LT2510012T (enExample)
MX (1) MX2012006593A (enExample)
NZ (1) NZ600470A (enExample)
PL (1) PL2510012T3 (enExample)
PT (1) PT2510012T (enExample)
RS (1) RS56161B1 (enExample)
RU (1) RU2577977C2 (enExample)
SI (1) SI2510012T1 (enExample)
TW (1) TWI488642B (enExample)
WO (1) WO2011070088A1 (enExample)
ZA (1) ZA201203498B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5881604B2 (ja) * 2010-06-15 2016-03-09 国立大学法人大阪大学 癌予後判定可能な抗体、および癌予後判定方法
TWI582112B (zh) 2011-04-21 2017-05-11 西雅圖遺傳學公司 新穎結合劑－藥物接合物（ＡＤＣｓ）及其用途（二）
JP2014117191A (ja) * 2012-12-13 2014-06-30 Fisheries Research Agency リン酸化中性スフィンゴミエリナーゼ１、抗リン酸化中性スフィンゴミエリナーゼ１抗体、中性スフィンゴミエリナーゼ１変異体、及びそれらの用途
AU2015315332A1 (en) * 2014-09-09 2017-03-30 Board Of Regents, The University Of Texas System Blocking monoclonal antibodies to AGR2 and its receptor C4.4A
WO2016166169A1 (en) * 2015-04-17 2016-10-20 Spring Bioscience Corporation Antibodies, compositions, and immunohistochemistry methods for detecting c4.4a
EP3383497A4 (en) * 2015-12-04 2019-06-12 The Regents of The University of California NOVEL ANTIBODIES FOR THE TREATMENT OF CANCER DISEASES
WO2017156280A1 (en) * 2016-03-09 2017-09-14 Viba Therapeutics, Inc. Methods of treating cancer using monoclonal antibodies to agr2 and c4.4a
US11993645B2 (en) 2017-01-11 2024-05-28 The Board Of Trustees Of The Leland Stanford Junior University Compositions comprising R-Spondin (RSPO) surrogate molecules
WO2018140821A1 (en) 2017-01-26 2018-08-02 Surrozen, Inc. Tissue-specific wnt signal enhancing molecules and uses thereof
JP7052389B2 (ja) * 2018-02-07 2022-04-12 株式会社三洋物産 遊技機
AU2019301633A1 (en) 2018-07-09 2021-01-28 Surrozen Operating, Inc. Tissue-specific Wnt signal enhancing molecules and uses
KR20210063319A (ko) * 2018-07-20 2021-06-01 듀크 유니버시티 암을 치료하기 위한 항-lypd3 car t-세포 요법
US20210324434A1 (en) * 2018-11-08 2021-10-21 National University Corporation Kagawa University Method for producing rare sugar-containing composition and rare sugar-containing composition
CN111349164B (zh) * 2018-12-21 2023-05-26 艾比玛特医药科技（上海）有限公司 糖基磷脂酰肌醇锚定糖蛋白（c4.4a）的单克隆抗体及其应用
WO2020257770A1 (en) 2019-06-21 2020-12-24 Children's National Medical Center Methods and composition for a binding molecule targeting cancer cells expressing ssx2 peptide 41-49 in hla-a*0201 context
EP4054602A4 (en) 2019-11-08 2023-12-06 Mayo Foundation for Medical Education and Research EPHA3 TARGETED CAR-T CELLS FOR TREATING TUMORS
JP2023549854A (ja) 2020-11-16 2023-11-29 スロゼン オペレーティング， インコーポレイテッド 肝臓特異的Ｗｎｔシグナル増強分子およびその使用
AU2023234686A1 (en) 2022-03-16 2024-08-29 Pentixapharm Ag Antibodies against lypd3
CA3258344A1 (en) 2022-06-07 2023-12-14 Actinium Pharmaceuticals Inc CHELETARIANS AND BIFUNCTIONAL CONJUGATES

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
CA2229043C (en) 1995-08-18 2016-06-07 Morphosys Gesellschaft Fur Proteinoptimierung Mbh Protein/(poly)peptide libraries
ES2169864T3 (es) * 1996-05-31 2002-07-16 Health Research Inc Anticuerpos monoclonales anti-endoglina y su uso en terapia anti-angiogenesis.
DE69937291T2 (de) 1998-04-02 2008-07-10 Genentech, Inc., South San Francisco Antikörpervarianten und fragmente davon
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
WO2001023553A2 (en) * 1999-09-29 2001-04-05 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Metastasis-associated antigen c4.4a
IL159177A0 (en) * 2001-06-20 2004-06-01 Prochon Biotech Ltd Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
MXPA06014065A (es) * 2004-06-01 2007-01-31 Genentech Inc Conjugados de droga-anticuerpo y metodos.
PL2117571T3 (pl) * 2006-12-08 2017-08-31 Monopar Therapeutics Inc. Epitop receptora aktywatora plazminogenu typu urokinazy
TWI582112B (zh) * 2011-04-21 2017-05-11 西雅圖遺傳學公司 新穎結合劑－藥物接合物（ＡＤＣｓ）及其用途（二）

Also Published As

Publication number Publication date
BR112012013915A8 (pt) 2017-12-26
US20170158775A1 (en) 2017-06-08
EP3144323A3 (en) 2017-05-31
PL2510012T3 (pl) 2017-09-29
US20120321619A1 (en) 2012-12-20
ZA201203498B (en) 2015-10-28
HRP20170973T1 (hr) 2017-09-22
IL219801A0 (en) 2012-07-31
JP2013513369A (ja) 2013-04-22
TW201134485A (en) 2011-10-16
LT2510012T (lt) 2017-07-25
PT2510012T (pt) 2017-07-13
JP2016104820A (ja) 2016-06-09
AR079340A1 (es) 2012-01-18
DK2510012T3 (en) 2017-07-31
TWI488642B (zh) 2015-06-21
EP3144323A2 (en) 2017-03-22
CN102812047B (zh) 2015-08-26
KR20120116958A (ko) 2012-10-23
CN102812047A (zh) 2012-12-05
NZ600470A (en) 2015-02-27
KR101931820B1 (ko) 2018-12-21
HK1178920A1 (en) 2013-09-19
AU2010329904A1 (en) 2012-06-14
WO2011070088A1 (en) 2011-06-16
IN2012DN05175A (enExample) 2015-10-23
EP2510012B1 (en) 2017-04-19
JP5989544B2 (ja) 2016-09-07
MX2012006593A (es) 2012-06-28
JP2018019721A (ja) 2018-02-08
HUE034847T2 (en) 2018-03-28
RU2012128343A (ru) 2014-01-20
IL219801A (en) 2016-08-31
JP6240696B2 (ja) 2017-11-29
EP2510012A1 (en) 2012-10-17
AU2010329904B2 (en) 2015-07-09
SI2510012T1 (sl) 2017-08-31
CA2783338A1 (en) 2011-06-16
BR112012013915A2 (pt) 2017-01-10
RU2577977C2 (ru) 2016-03-20
ES2632748T3 (es) 2017-09-15
RS56161B1 (sr) 2017-11-30

Similar Documents

Publication Publication Date Title
CY1119051T1 (el) Αντισωματα anti-c4.4a και χρησεις αυτων
CY1117437T1 (el) Αντισωματα αντι-μεσοθηλινης και χρησεις αυτων
CY1125427T1 (el) Anti-gm-csf αντισωματα και χρησεις αυτων
CY1123165T1 (el) Ανοσοσυζευγματα αντι-μεσοθηλινης και χρησεις αυτων
EA202092735A1 (ru) Антагонизирующее cd73 антитело
EA201892616A1 (ru) Антитела к pd1 и lag3 для лечения злокачественного новообразования
CL2019002717A1 (es) Receptores de unión a antígeno mejorados.
CY1124209T1 (el) Συνθεσεις anti-cgrp και χρησεις αυτων
CY1122627T1 (el) Αντισωματα εναντι της ceacam6 και χρησεις αυτων
CY1116458T1 (el) Ανθρωπινα αντισωματα anti-cd38 και οι χρησεις εξ' αυτων
MX2020001080A (es) Anticuerpos con dominios funcionales en la region del codo entre el dominio variable y constante.
MX2021015888A (es) Fusión de un anticuerpo que se une a cea y 4-1bbl.
MX2015016814A (es) Anticuerpo anti-tweakr y sus usos.
EA201790799A1 (ru) Композиции и способы для применения для усиления иммунного ответа и терапии злокачественных опухолей
MX2020008795A (es) Anti cuerpos anti tigit y usos de los mismos.
GEP20237466B (en) Methods of inhibiting angiogenesis in patient
EA201992038A1 (ru) Анти-псф-тау-антитела и способы их применения
EA201591091A1 (ru) Антигенсвязывающие белки для bcma
CY1118608T1 (el) Αντισωματα για θεραπευτικη αγωγη καρκινου που εκφραζει κλαυδινη 6
EA201300470A1 (ru) Антитела
EA201791050A1 (ru) Конъюгаты антител и лекарственных средств
EA201101516A1 (ru) Антитела, специфические для кадгерина-17
PE20180480A1 (es) Anticuerpos de factor xi y metodos de uso
EA201590986A1 (ru) Антитела к ceacam5 и их применения
BR112018005573A2 (pt) ?polipeptídeos de ligação a cd3?